Cirrhosis Regression and Subclassification

Surgical Pathology Clinics

Volumn 6, Issue 2, 2013, Pages 295-309

  Bedossa, Pierre ^a   Garcia Tsao, Guadalupe ^b   Jain, Dhanpat ^b  

^a BEAUJON HOSPITAL   (France)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Fibrosis; Liver; Regression

Indexed keywords

AZATHIOPRINE; CARBON TETRACHLORIDE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; NEUTROPHIL COLLAGENASE; PREDNISOLONE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3;

ALCOHOL LIVER CIRRHOSIS; ANGIOGENESIS; BILIARY TRACT DRAINAGE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ELASTOGRAPHY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROGENESIS; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INTOXICATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PHLEBOTOMY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REMISSION; REVIEW; TREATMENT DURATION; VIRUS REPLICATION;

EID: 84878493421     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2013.03.006     Document Type: Review

References (71)

1. Bedossa P., Paradis V. Liver extracellular matrix in health and disease. J Pathol 2003, 200:504-515.
2. Anthony P.P., Ishak K.G., Nayak N.C., et al. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978, 31:395-414.
3. Ratziu V., Voiculescu M., Poynard T. Touching some firm ground in the epidemiology of NASH. J Hepatol 2012, 56:23-25.
4. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463-472.
5. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
6. Friedman S.L., Bansal M.B. Reversal of hepatic fibrosis - fact or fantasy?. Hepatology 2006, 43:S82-S88.
7. Perez-Tamayo R. Cirrhosis of the liver: a reversible disease?. Pathol Annu 1979, 14(Pt 2):183-213.
8. Wanless I.R., Nakashima E., Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000, 124:1599-1607.
9. Serpaggi J., Carnot F., Nalpas B., et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006, 37:1519-1526.
10. Reichard O., Glaumann H., Fryden A., et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999, 30:783-787.
11. Shiratori Y., Imazeki F., Moriyama M., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-524.
12. George S.L., Bacon B.R., Brunt E.M., et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-738.
13. D'Ambrosio R., Aghemo A., Rumi M.G., et al. Histological findings among HCV cirrhotic patients who achieved a SVR: a morphometric and immunohistochemical study. Hepatology 2011, 54:1229A.
14. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
15. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
16. Chang T.T., Liaw Y.F., Wu S.S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010, 52:886-893.
17. Fauerholdt L., Schlichting P., Christensen E., et al. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology 1983, 3:928-931.
18. Czaja A.J., Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004, 40:646-652.
19. Cotler S.J., Jakate S., Jensen D.M. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001, 32:428-430.
20. Niederau C., Fischer R., Purschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110:1107-1119.
21. Hammel P., Couvelard A., O'Toole D., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001, 344:418-423.
22. Chavez-Tapia N.C., Tellez-Avila F.I., Barrientos-Gutierrez T., et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010, (1). CD007340.
23. Schuppan D., Pinzani M. Anti-fibrotic therapy: lost in translation?. J Hepatol 2012, 56(Suppl 1):S66-S74.
24. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
25. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
26. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
27. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
28. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
29. Wong G.L., Yiu K.K., Wong V.W., et al. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 2010, 32:1059-1068.
30. Mallet V., Gilgenkrantz H., Serpaggi J., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008, 149:399-403.
31. Arthur M.J. Collagenases and liver fibrosis. J Hepatol 1995, 22:43-48.
32. Bataller R., Gabele E., Parsons C.J., et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005, 41:1046-1055.
33. Theret N., Musso O., L'Helgoualc'h A., et al. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am J Pathol 1997, 150:51-58.
34. Uchinami H., Seki E., Brenner D.A., et al. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006, 44:420-429.
35. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427-436.
36. Benyon R.C., Iredale J.P., Goddard S., et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996, 110:821-831.
37. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001, 21:311-335.
38. de Leeuw A.M., McCarthy S.P., Geerts A., et al. Purified rat liver fat-storing cells in culture divide and contain collagen. Hepatology 1984, 4:392-403.
39. Saile B., Knittel T., Matthes N., et al. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol 1997, 151:1265-1272.
40. Iredale J.P., Benyon R.C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538-549.
41. Gaca M.D., Zhou X., Issa R., et al. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol 2003, 22:229-239.
42. Taimr P., Higuchi H., Kocova E., et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003, 37:87-95.
43. Issa R., Zhou X., Constandinou C.M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808.
44. Rudolph K.L., Chang S., Millard M., et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000, 287:1253-1258.
45. Paradis V., Youssef N., Dargere D., et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 2001, 32:327-332.
46. Kweon Y.O., Goodman Z.D., Dienstag J.L., et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749-755.
47. Hytiroglou P., Snover D.C., Alves V., et al. Beyond " cirrhosis" : a proposal from the International Liver Pathology Study Group. Am J Clin Pathol 2012, 137:5-9.
48. Garcia-Tsao G., Friedman S., Iredale J., et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010, 51:1445-1449.
49. Ripoll C., Groszmann R., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007, 133:481-488.
50. Garcia-Tsao G., Groszmann R.J., Fisher R.L., et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985, 5:419-424.
51. Morali G.A., Sniderman K.W., Deitel K.M., et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. J Hepatol 1992, 16:249-250.
52. Blasco A., Forns X., Carrion J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43:492-499.
53. Garcia-Pagan J.C., Bosch J. Monitoring of HVPG during pharmacological therapy: evidence in favor of the prognostic value of a 20% reduction. Hepatology 2004, 39:1746-1747. [author reply: 1747].
54. Ripoll C., Groszmann R.J., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009, 50:923-928.
55. Saleh H.A., Abu-Rashed A.H. Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis 2007, 16:425-426.
56. Madan K. Is liver biopsy still the gold standard for diagnosing liver fibrosis?. Trop Gastroenterol 2011, 32:253-255.
57. Carrion J.A., Navasa M., Bosch J., et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006, 12:1791-1798.
58. Berg T., Sarrazin C., Hinrichsen H., et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology 2004, 39:1456-1457. [author reply: 1457-8].
59. Calvaruso V., Burroughs A.K., Standish R., et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009, 49:1236-1244.
60. Sethasine S., Jain D., Groszmann R.J., et al. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology 2012, 55:1146-1153.
61. Kumar M., Sakhuja P., Kumar A., et al. Histological subclassification of cirrhosis based on histological-haemodynamic correlation. Aliment Pharmacol Ther 2008, 27:771-779.
62. Sreenivasan P., Inayat I., Deng Y., et al. Histological-clinical correlation in cirrhosis-validation of a histological classification of the severity of cirrhosis. Hepatology 2007, 46(Suppl 1):579A.
63. Goodman Z.D., Stoddard A.M., Bonkovsky H.L., et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009, 50:1738-1749.
64. Nagula S., Jain D., Groszmann R.J., et al. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006, 44:111-117.
65. Wanless I.R., Sweeney G., Dhillon A.P., et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002, 100:1566-1569.
66. Kutami R., Girgrah N., Wanless I.R., et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology 2000, 32:407A.
67. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006, 44:217-231.
68. Kim M.Y., Cho M.Y., Baik S.K., et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011, 55:1004-1009.
69. Xu B., Broome U., Uzunel M., et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol 2003, 163:1275-1289.
70. Masseroli M., Caballero T., O'Valle F., et al. Automatic quantification of liver fibrosis: design and validation of a new image analysis method: comparison with semi-quantitative indexes of fibrosis. J Hepatol 2000, 32:453-464.
71. Goodman Z.D., Becker R.L., Pockros P.J., et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007, 45:886-894.